Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Tuberous sclerosis, also called tuberous sclerosis complex (TSC), is described in the packet as a hereditary disease characterized by seizures, intellectual disability, developmental delay, and skin and ocular lesions. First signs usually occur during infancy or childhood but in rare cases may not occur until the second or third decade. According to GeneReviews, TSC involves abnormalities primarily of the skin, brain, kidneys, heart, and lungs, although any organ system can be involved, and it shows both inter- and intrafamilial variability. The packet lists a prevalence category of uncommon, with an estimate of 1 to 9 in 100,000. GeneReviews states that incidence may be as high as 1 in 5,800 live births but is generally estimated between 1 in 6,000 and 1 in 10,000 live births. The packet lists two subtypes, tuberous sclerosis 1 and tuberous sclerosis 2.
A structured phenotype list is not populated in the packet, so the following is drawn from the packet definition and the GeneReviews clinical description. GeneReviews reports skin involvement in virtually 100% of individuals, including hypomelanotic macules (about 90%), facial angiofibromas (about 75%), shagreen patches (about 50%), and ungual fibromas (20% overall, up to 80% in older affected adults), along with fibrous cephalic plaques and "confetti" skin lesions. Central nervous system findings include subependymal nodules and cortical tubers (each about 80%) and subependymal giant cell astrocytoma (up to 25%). More than 80% of individuals are reported to have seizures, with up to 75% developing seizures before age two years, and about two thirds experiencing drug-resistant epilepsy. TSC-associated neuropsychiatric disorder, covering behavioral, psychiatric, intellectual, academic, neuropsychological, and psychosocial difficulties, is listed at 90%. Kidney findings include benign renal angiomyolipoma (70%), epithelial cysts (20% to 30%), and renal cell carcinoma (3%). Cardiac rhabdomyomas are listed at 47% to 67%, lymphangioleiomyomatosis in up to 80% of females, and retinal lesions at 30% to 50%.
No genes are listed in the packet's gene field, and no inheritance patterns are recorded there, although the packet lists subtypes numbered 1 and 2. The GeneReviews chapter states that TSC is inherited in an autosomal dominant manner. GeneReviews reports that about one third of individuals diagnosed with TSC have an affected parent, and that two thirds have the disorder as the result of a de novo pathogenic variant. It describes the possibility of parental gonadal mosaicism, reported in several families, and notes that a parent with somatic and gonadal mosaicism may be mildly or minimally affected. GeneReviews states that the penetrance of TSC appears to be 100%, with rare instances of apparent non-penetrance in which molecular studies revealed other explanations. It also describes mTOR inhibitors as replacing the function within the cell normally provided by the hamartin/tuberin multimer.
GeneReviews describes consensus clinical diagnostic criteria for TSC, in which the condition is suspected with one major feature or two or more minor features. Major features listed include hypomelanotic macules, angiofibromas or fibrous cephalic plaque, shagreen patch, ungual fibromas, subependymal nodules, multiple cortical tubers or radial migration lines, subependymal giant cell astrocytoma, renal angiomyolipomas, cardiac rhabdomyoma, lymphangioleiomyomatosis, and multiple retinal nodular hamartomas. Minor features listed include "confetti" skin lesions, sclerotic bone lesions, dental enamel pits, intraoral fibromas, multiple renal cysts, extrarenal hamartomas, and retinal achromic patch. A definite clinical diagnosis is described as established with two major features, or one major feature with two or more minor features, and the combination of lymphangioleiomyomatosis and renal angiomyolipomas alone is noted as not meeting the criteria. GeneReviews also describes a molecular diagnosis established by identification of a heterozygous pathogenic or likely pathogenic variant on molecular genetic testing, and notes that because clinical manifestations develop over time, such a variant is sufficient to establish the diagnosis. The packet lists no newborn screening information for this condition.
The packet lists active FDA records for sirolimus (Hyftor, approved March 2022), cannabidiol (Epidiolex, approved June 2018), and everolimus (Afinitor Disperz, approved August 2012, and Afinitor, approved March 2009). The packet's orphan drug records describe Epidiolex with an approved indication of treatment of tuberous sclerosis complex, and Afinitor with an approved indication covering TSC-associated subependymal giant cell astrocytoma, angiomyolipoma, and lymphangioleiomyomatosis. Orphan designations, which are not approvals, are recorded for everolimus ointment, ganaxolone, rapamycin, sirolimus products (including one for TSC-related facial angiofibromas), and vigabatrin. GeneReviews describes mTOR inhibitors (sirolimus and everolimus) as the targeted therapy class for TSC, and describes supportive care involving multidisciplinary specialists. It describes mTOR inhibitor treatment as the primary therapy for growing or large subependymal giant cell astrocytomas causing mild-to-moderate symptoms, and that surgery with cerebrospinal fluid diversion may be required for acute deterioration due to obstructive hydrocephalus. GeneReviews also reports that the EXIST-1 trial found everolimus treatment resulted in a 30% reduction in tumor volume in 65% to 79% of individuals, maintained for up to three years. GeneReviews describes consensus surveillance schedules covering skin, brain, kidney, heart, lung, eye, seizure, and neuropsychiatric manifestations. Patient assistance programs may be available for some therapies.
38 trials found
Prognosis is described only in general terms in the packet. GeneReviews states that central nervous system-related problems, including TSC-associated neuropsychiatric disorder, are the leading cause of morbidity, whereas kidney disease is the leading cause of mortality. It notes variability within and between families. GeneReviews associates early recognition and control of seizures with improved developmental and neurologic outcomes in infants, and notes that developmental delays, autism spectrum disorder, and psychiatric disorders show a strong association with early-onset and drug-resistant epilepsy. Individual outcomes are not certified in this packet.
ClinicalTrials.gov records in the packet include studies that are recruiting, not yet recruiting, and active but not recruiting. TSC-focused records include a sirolimus study on prevention of epilepsy onset, a comparison of rapamycin and vigabatrin in preventing symptoms in infants, a placebo-controlled rapamycin study in drug-resistant epilepsy, a phase 2 study of an investigational agent in refractory epilepsy, a long-term liver safety study of cannabidiol oral solution, and long-running National Heart, Lung, and Blood Institute studies on lymphangioleiomyomatosis, lung disease genetics, and skin tumors. Other records address the prevalence and clinical characteristics of neurocutaneous syndromes in children and a web-based intervention for parents of youth with genetic syndromes. The packet's trial summary lists drug therapy, medical devices, procedural interventions, and other interventions, and indicates gene therapy trials are present. Its publication landscape summary classifies basic science and preclinical work as the dominant research type.
Data assembled from 6 of 12 sources · Last updated Nov 17, 2026, 6:46 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning tuberous sclerosis
Updated Sep 6, 2026
A new study explores the lived experiences of individuals with tuberous sclerosis complex in Ireland, highlighting the challenges faced in obtaining a diagnosis. The findings emphasize the emotional impact of navigating this rare disease and the importance of timely diagnosis.
A recent publication discusses rare genetic endocrine tumor syndromes, including von Hippel-Lindau (VHL), neurofibromatosis type 1 (NF1), tuberous sclerosis complex (TSC), and Carney complex. The review highlights the genetic underpinnings and clinical implications of these conditions.
A recent study published in PubMed discusses a case of tuberous sclerosis complex in a 14-year-old male with a congenitally right solitary kidney. This case adds to the understanding of the disease's manifestations and potential complications.